Vivitra 150 mg Injection
Vivitra 150 mg Injection contains trastuzumab, a targeted monoclonal antibody used mainly for HER2-positive breast and gastric cancers. It is supplied as a 150 mg injection and is administered by intravenous infusion under medical supervision. Trastuzumab targets the HER2 protein and helps slow the growth of HER2-positive cancer cells.
Technical Specification
| Specification | Details |
|---|---|
| Active Ingredient | Trastuzumab |
| Strength | 150 mg |
| Dosage Form | Injection |
| Route of Administration | Intravenous Infusion |
| Pack Size | 1 Vial |
| Manufacturer | Zydus Lifesciences Limited |
Product Also Known As









